Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Comm...
June 22 2020 - 7:00AM
Business Wire
– Dr. Young to strengthen commercial expertise
ahead of SER-109 Phase 3 data readout, and to maximize the
potential of Seres’ microbiome therapeutic pipeline –
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the
appointment of Terri Young, Ph.D., R.Ph., as Executive Vice
President, Chief Commercial and Strategy Officer, effective June
29, 2020. Dr. Young brings to Seres over 20 years of commercial and
marketing leadership experience, having successfully led the growth
of several important biopharmaceutical products.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200622005155/en/
Terri Young, Ph.D., R.Ph. (Photo:
Business Wire)
“We are thrilled to welcome Terri to the Seres team ahead of our
anticipated, potentially pivotal SER-109 ECOSPOR III Phase 3 study
readout in patients with recurrent C. difficile infection. Terri’s
extensive marketing and sales leadership experience will be
invaluable as we continue to prepare for the potential
commercialization of SER-109,” said Eric Shaff, President and Chief
Executive Officer of Seres. “In addition to SER-109, Terri will
support the advancement of our overall microbiome therapeutic
pipeline targeting infectious diseases, immunological conditions
and cancer. In particular, we look forward to Terri’s contributions
on our promising SER-287 program, which is in a Phase 2b study for
ulcerative colitis.”
“I am excited to join Seres as the Company prepares for the
potential commercialization of SER-109. Recurrent C. difficile is a
condition where improved treatment options are urgently needed, and
SER-109 has the potential to fundamentally transform how patients
are managed,” said Dr. Young. “In addition to SER-109, Seres is
advancing an innovative pipeline of microbiome therapeutic
candidates, including SER-287 and SER-301 for ulcerative colitis
and SER-401 and SER-155 for cancer. I look forward to working with
the team to implement strategies that maximize the enormous
potential of this novel therapeutic modality.”
Prior to joining Seres, Dr. Young served as Vice President,
Global Commercial Strategy at Sage Therapeutics, where she led
development of Sage’s global commercial capabilities, including
global marketing, insights and analytics and new product planning.
Previously, she held commercial leadership roles of increasing
responsibility at Bristol-Myers Squibb, culminating in her role as
Vice President and General Manager, Cardiovascular, in which she
led the global ELIQUIS® business to become the company’s largest
product by revenue. Earlier in her career, Dr. Young held marketing
and sales roles at GlaxoSmithKline, where she catalyzed growth for
the company’s Urology, Diabetes and NeuroHealth organizations. Dr.
Young received her B.S. in pharmacy and her Ph.D. in healthcare
marketing from the University of South Carolina. Dr. Young is a
member of the Women in Bio and Healthcare Businesswomen’s
Association, and served on the Advisory Board of the Healthcare
Businesswomen’s Association.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome
therapeutics platform company developing a novel class of
biological drugs that are designed to treat disease by restoring
the function of a dysbiotic microbiome, where the state of
bacterial diversity and function is imbalanced. Seres’ SER-109
program has obtained Breakthrough Therapy and Orphan Drug
designations from the FDA and is in Phase 3 development for
recurrent C. difficile infection. Seres’ SER-287 program has
obtained Fast Track and Orphan Drug designation from the U.S. Food
and Drug Administration and is being evaluated in a Phase 2b study
in patients with active mild-to-moderate ulcerative colitis. Seres
is developing SER-401 in a Phase 1b study in patients with
metastatic melanoma, SER-301 for ulcerative colitis, and SER-155 to
prevent mortality due to gastrointestinal infections, bacteremia
and graft versus host disease. For more information, please visit
www.serestherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including the timing and results of
each of Seres’ clinical studies, Seres’commercialization plans, the
promise and potential impact of microbiome therapeutics and other
statements that are not historical facts.
These forward-looking statements are based on management’s
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: We have incurred significant losses, are not currently
profitable and may never become profitable; our need for additional
funding; our limited operating history; the ability to develop and
commercialize our product candidates, if approved; the potential
impact of the COVID-19 pandemic; our ability to retain key
personnel and to manage our growth; and that our management and
principal stockholders have the ability to control or significantly
influence our business. These and other important factors discussed
under the caption “Risk Factors” in our Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission, or SEC, on
May 7, 2020 and our other reports filed with the SEC could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views
to change. These forward-looking statements should not be relied
upon as representing our views as of any date subsequent to the
date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200622005155/en/
PR Contact Lisa Raffensperger
lisa@tenbridgecommunications.com IR Contact Carlo Tanzi,
Ph.D. ctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024